An osmotic-controlled oral pharmaceutical composition providing delayed release of a therapeutically effective amount of an active pharmaceutical ingredient, the composition comprising: a) a multilayered core comprising a placebo layer, an active layer, and a push layer, wherein: (i) the placebo layer comprises at least one low molecular weight polyethylene oxide polymer having an average molecular weight of about 100K, about 200K, about 300K, about 600K, about 900K, or intermediate values thereof, (ii) the active layer comprises an active pharmaceutical agent, and at least one low molecular weight polyethylene oxide polymer having an average molecular weight of about 100K, about 200K, about 300K, about 600K, or intermediate values thereof, (iii) the push layer comprises an osmogen and at least one high molecular weight polyethylene oxide polymer having an average molecular weight of about 1M, about 2M, about 4M, about 5M, about 7M, or intermediate values thereof; and b) a semipermeable membrane, containing an orifice and surrounding the core, wherein the layers in the multilayer core are placed in the following order: the placebo layer in fluid communication with the orifice in the semipermeable membrane; the active layer; and the push layer facing away from the orifice, wherein when the composition is placed in 900 ml of a dissolution medium comprising 0.01N HCl at a pH of about 2.0 for up to 24 hours, the composition provides a lag time of at least 6 hours during which the composition releases no more than 10% of the active pharmaceutical ingredient, followed by extended release of the active pharmaceutical agent for about 10-16 hours, as measured in USP Apparatus II at 37°C and agitation at 50 rpm, wherein the composition provides a drug recovery of at least about 90% at about 22 hours from the time of administration into the dissolution medium, and wherein the composition exhibits minimal variability in the lag time with variations in pH, volume of the dissolution medium, and/or the viscosity of the dissolution medium, wherein "about" means ±10%. a) a multilayered core comprising a placebo layer, an active layer, and a push layer, wherein: (i) the placebo layer comprises at least one low molecular weight polyethylene oxide polymer having an average molecular weight of about 100K, about 200K, about 300K, about 600K, about 900K, or intermediate values thereof, (ii) the active layer comprises an active pharmaceutical agent, and at least one low molecular weight polyethylene oxide polymer having an average molecular weight of about 100K, about 200K, about 300K, about 600K, or intermediate values thereof, (iii) the push layer comprises an osmogen and at least one high molecular weight polyethylene oxide polymer having an average molecular weight of about 1M, about 2M, about 4M, about 5M, about 7M, or intermediate values thereof; and (i) the placebo layer comprises at least one low molecular weight polyethylene oxide polymer having an average molecular weight of about 100K, about 200K, about 300K, about 600K, about 900K, or intermediate values thereof, (ii) the active layer comprises an active pharmaceutical agent, and at least one low molecular weight polyethylene oxide polymer having an average molecular weight of about 100K, about 200K, about 300K, about 600K, or intermediate values thereof, (iii) the push layer comprises an osmogen and at least one high molecular weight polyethylene oxide polymer having an average molecular weight of about 1M, about 2M, about 4M, about 5M, about 7M, or intermediate values thereof; and b) a semipermeable membrane, containing an orifice and surrounding the core, wherein the layers in the multilayer core are placed in the following order: the placebo layer in fluid communication with the orifice in the semipermeable membrane; the active layer; and the push layer facing away from the orifice, wherein when the composition is placed in 900 ml of a dissolution medium comprising 0.01N HCl at a pH of about 2.0 for up to 24 hours, the composition provides a lag time of at least 6 hours during which the composition releases no more than 10% of the active pharmaceutical ingredient, followed by extended release of the active pharmaceutical agent for about 10-16 hours, as measured in USP Apparatus II at 37°C and agitation at 50 rpm, wherein the composition provides a drug recovery of at least about 90% at about 22 hours from the time of administration into the dissolution medium, and wherein the composition exhibits minimal variability in the lag time with variations in pH, volume of the dissolution medium, and/or the viscosity of the dissolution medium, wherein "about" means ±10%. wherein the layers in the multilayer core are placed in the following order: the placebo layer in fluid communication with the orifice in the semipermeable membrane; the active layer; and the push layer facing away from the orifice, wherein when the composition is placed in 900 ml of a dissolution medium comprising 0.01N HCl at a pH of about 2.0 for up to 24 hours, the composition provides a lag time of at least 6 hours during which the composition releases no more than 10% of the active pharmaceutical ingredient, followed by extended release of the active pharmaceutical agent for about 10-16 hours, as measured in USP Apparatus II at 37°C and agitation at 50 rpm, wherein the composition provides a drug recovery of at least about 90% at about 22 hours from the time of administration into the dissolution medium, and wherein the composition exhibits minimal variability in the lag time with variations in pH, volume of the dissolution medium, and/or the viscosity of the dissolution medium, wherein "about" means ±10%.